

Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 67.04 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 94.42 | Oscillator | Sell |
| Williams %R (14) | -4.72 | Oscillator | Sell |
| MACD (12, 26, 9) | 0.59 (Hist 0.32) | Oscillator | Strong Buy |
| Average Directional Index (14) | 26.78 (+DI 28.9 / -DI 11.9) | Trend | Strong Buy |
| EMA 20 | 39.47 | MA | Strong Buy |
| SMA 20 | 38.90 | MA | Strong Buy |
| EMA 50 | 39.51 | MA | Strong Buy |
| SMA 50 | 39.01 | MA | Strong Buy |
| SMA 200 | 41.48 | MA | Sell |
Stock news · updated daily
CNP's Q3 earnings are likely to benefit from grid investments, rising electricity demand and rate-base growth, while higher financing costs could offset gains.
Louisbourg Investments Inc. lowered its position in shares of CenterPoint Energy, Inc. (NYSE: CNP) by 45.1% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 17,760 shares of the utilities provider's stock after selling 14,574 shares during the quarter. Louisbourg Investments Inc.'s holdings in CenterPoint
CenterPoint (CNP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
COPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for once-weekly TransCon CNP (navepegritide) in the European Union for the treatment of achondroplasia in children two years of age and older whose epiphyses are not closed. The final European Commission (EC) decision on Ascendis Pharma's Marketing Authorisation Application (MAA) is expected during Q4 2026.
HOUSTON--(BUSINESS WIRE)--CenterPoint Energy, Inc. (NYSE: CNP) has established October 21, 2026 as an Additional Interest Regular Record Date under the terms of its 2.0 percent Zero-Premium Exchangeable Subordinated Notes due 2029 (ZENS). Additional Interest of $5.39122 per ZENS note will be paid on November 4, 2026 to holders of record of the ZENS as of the close of business on the Additional Interest Regular Record Date. The payment of Additional Interest reflects cash distributed in respect.
CenterPoint Energy Sending 355 Mutual Aid Workers to Help Restore Power in Areas Impacted by Hurricane IsaiasPR NewswireHOUSTON, Oct. 10, 2026Frontline personne
Frontline personnel and contractors deploying to help support Florida Power & Light withexpected outages along the Florida Gulf Coast HOUSTON, Oct. 10, 2026 /PRNewswire/ -- To help support customers and communities impacted by Hurricane Isaias along the Northwest Florida Coast, CenterPoint Energy crews are heading out to play an important role in helping neighboring communities recover by restoring Hurricane Isaias-related outages. Through a mutual assistance effort supporting Florida Power & Light, CenterPoint has deployed 105 line workers and released approximately 150 contractor line workers and 100 vegetation management personnel to assist with restoration efforts in Pensacola.
Here is how CenterPoint Energy (CNP) and Consolidated Edison (ED) have performed compared to their sector so far this year.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 28, 2026 | 0.37 | 0.40 | Beat 7.2% | $2.15B |
| Apr 23, 2026 | 0.55 | 0.56 | Beat 2.0% | $2.98B |
| Feb 19, 2026 | 0.45 | 0.45 | Beat 0.0% | $2.49B |
| Oct 23, 2025 | 0.45 | 0.50 | Beat 10.9% | $1.96B |
| Jul 24, 2025 | 0.38 | 0.29 | Miss -24.5% | $1.94B |
| Apr 24, 2025 | 0.55 | 0.53 | Miss -3.6% | $2.92B |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 1, 26 | Clark Lauren Chesley | officer: EVP and CHRO | A-Award | 32,249 | — |
| Oct 1, 26 | Clark Lauren Chesley | officer: EVP and CHRO | 0 | — | |
| Aug 17, 26 | Fitch Laurie Lee | director | P-Purchase | 1,000 @ $40.70 | $40.70K |
| Aug 11, 26 | Wright Russell Keith | officer: VP and CAO | F-InKind | 211 @ $40.18 | $8.48K |
| Aug 11, 26 | Soto Jesus Jr. | officer: EVP and COO | F-InKind | 15,151 @ $40.18 | $608.8K |
| Aug 11, 26 | Soto Jesus Jr. | officer: EVP and COO | F-InKind | 1,924 @ $40.18 | $77.31K |
| May 5, 26 | Foster Christopher A | officer: EVP and CFO | F-InKind | 5,867 @ $43.53 | $255.4K |
| May 1, 26 | Malik Thaddeus J. | director | A-Award | 4,037 | — |
FY2025 · 10-K disclosure
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 20, 2026 | 2026-10-20 16:18:27 | View |
| 4 | Oct 5, 2026 | 2026-10-05 16:22:46 | View |
| 3 | Oct 5, 2026 | 2026-10-05 16:20:56 | View |
| 8-K | Oct 1, 2026 | 2026-10-01 06:51:29 | View |
| 8-K | Sep 14, 2026 | 2026-09-14 17:15:58 | View |
| 8-K | Sep 9, 2026 | 2026-09-09 16:30:47 | View |
| 4 | Aug 18, 2026 | 2026-08-18 16:27:03 | View |
| 4 | Aug 13, 2026 | 2026-08-13 16:33:44 | View |
| 4 | Aug 13, 2026 | 2026-08-13 16:32:53 | View |
| SC 13G/A | Aug 12, 2026 | 2026-08-12 10:28:16 | View |
Proxy statement (DEF 14A) disclosures
Annual filings (FY) with consensus forward estimates (hatched)
Current price $41.07
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 21, 26 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| Oct 19, 26 | Barclays | maintain | Equal Weight | Equal Weight |
| Oct 19, 26 | BMO Capital | maintain | Outperform | Outperform |
| Oct 13, 26 | JP Morgan | maintain | Neutral | Neutral |
| Oct 13, 26 | Keybanc | maintain | Overweight | Overweight |
| Oct 12, 26 | Truist Securities | maintain | Buy | Buy |
| Oct 8, 26 | Citigroup | maintain | Neutral | Neutral |
| Sep 18, 26 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| Aug 21, 26 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
TTM vs. 5-year historical average (annual ratios)
| Metric | CNP | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 24.2x | 19.1x · sector 27.3x | In line |
| Forward P/E (FY26E) | 21.5x | EPS est. 1.91 | In line |
| Price / Book | 2.3x | 1.9x | Elevated |
| Price / Sales | 2.8x | 2.2x | Elevated |
| EV / EBITDA | 13.0x | 12.0x | In line |
| Return on equity | 9.9% | — | Weak |
| Gross margin | 54.1% | 38.4% | Above hist. |
| Debt / Equity | 2.14 | 1.88 | Levered |
| Piotroski / Altman Z | 6/9 | Z 0.89 | Distress |
Discounted cash flow model